TY - JOUR
T1 - TCR-like antibodies in cancer immunotherapy
AU - He, Qinghua
AU - Liu, Zhaoyu
AU - Liu, Zhihua
AU - Lai, Yuxiong
AU - Zhou, Xinke
AU - Weng, Jinsheng
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/9/14
Y1 - 2019/9/14
N2 - Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.
AB - Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.
KW - Antibody
KW - Immunotherapy
KW - T cell receptor
KW - TCR-like antibody
KW - Tumor antigen
UR - http://www.scopus.com/inward/record.url?scp=85072156401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072156401&partnerID=8YFLogxK
U2 - 10.1186/s13045-019-0788-4
DO - 10.1186/s13045-019-0788-4
M3 - Review article
C2 - 31521180
AN - SCOPUS:85072156401
SN - 1756-8722
VL - 12
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 99
ER -